Predict your next investment

HEALTHCARE | Biotechnology

See what CB Insights has to offer

Founded Year



Grant - II | Alive

Total Raised


Last Raised

$140K | 16 yrs ago

About SimuGen

Developer of predictive toxicology products. The company is a drug discovery pharmacogenomics company focused on predicting human safety earlier. It combines groundbreaking human cell culture and genomic modelling to produce high throughput screens for use alongside other early ADME testing.

SimuGen Headquarter Location

83 Victoria Street

London, SW1H 0HW,

United Kingdom

44 203 326 4283

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.